- Scientist of international
reputation
- Former Head of Oncology Research at
Novartis
- "Curiox establishes itself"
Frankfurt / Singapore – July
27, 2009
Prof. Dr. Alex Matter has joined the Board of Directors of Singaporean
Nanostart holding Curiox Biosystems. Dr. Matter is best known for his
contribution to the development of Glivec/Gleevec¢ē, one of the world's
first tyrosine kinase inhibitor drugs against chronic myeloid leukemia (CML).
Starting in the mid-eighties, Dr. Matter led a team of close to 200
scientists at Novartis to discover and optimize the lead compound and
brought it all the way through its first clinical trial in 1998. In a
short span of 3 years, Glivec/Gleevec¢ē was given a very rare, fast
track FDA approval in 2001.
He was the founding director of the
Novartis Institute for Tropical Diseases and is Chief Executive Officer
of the Experimental Therapeutics Centre (ETC), both located in
Singapore. During his long career in the pharmaceutical industry Dr.
Matter has held several positions of responsibility such as Head of
Pharmaceutical Research at Hoffman-LaRoche, Head of Cancer and Viral
Research at CIBA-GEIGY and more recently Global Head of Oncology
Research, at Novartis Pharmaceuticals Corporation. Dr. Alex Matter,
received his medical degree from the University of Basel. He has
authored over 100 scientific articles and book chapters in the areas of
oncology and hematology. He is the recipient of the 13th Warren-Alpert
prize in 2000 and the AACR-Bruce F. Cain Memorial Award.
Matter comments his service in the
Board of Directors of Curiox: "I am looking forward to work with
Curiox which pursues innovative, cutting-edge technologies in the field
of high throughput screening and establishes itself in a rapidly growing
hightech market segment."
Namyong Kim, CEO of Curiox, believes
that Matter¢„s huge experience and network will assure the success of
new DropArray™ products that are going to be launched in the next
few months for the pharmaceutical and biotech market. Kim says: "The
ready acceptance of the invitation by Dr. Matter in joining the Board
shows the strength and promise of Curiox's unique DropArray™
technology in innovating the ways of preclinical drug discovery are
performed. I look forward to working with him in building Curiox into
one of major bioinstrumentation companies."
About Nanostart:
Nanostart AG is the world's leading
nanotechnology investment company. The Frankfurt-based company provides
venture capital financing for nanotechnology companies in various growth
phases. It also provides the benefits of its experience and expertise to
developers of financial instruments and to investors in the
nanotechnology sector. For further information about the company, please
visit www.nanostart.de.
About Curiox
Curiox Biosystems has a vision to
accelerate the progress of life sciences and drug discovery through
better miniaturization. Curiox is a bioinstrumentation company enabling
the miniaturization of heterogeneous bioassay for researchers working in
life sciences, drug discovery, and diagnostics. Curiox's patented
miniaturization platform, DropArray™, provides up to 1,000 times
savings in sample and reagent consumption, and up to 10 times reduction
in assay time. The company is located at Biopolis in Singapore, the
biomedical hub of Singapore and Southeast Asia. The company is a
spin-off from Institute of Bioengineering and Nanotechnology (IBN)
backed primarily by Nanostart and Exploit Technologies, the
commercializing arm of Singapore's Agency for Science, Technology and
Research (A*STAR). For further information, please visit www.curiox.com.
Disclaimer:
This notice constitutes neither an
offer to sell nor a solicitation of offers to purchase or subscribe to
securities. There will be no public offering of securities of Nanostart
AG in conjunction with the existing listing of its shares in the "Entry
Standard" segment of the regulated unofficial market (Freiverkehr) on
the Frankfurt Stock Exchange. This notice does not constitute a
securities prospectus. Neither this notice nor the information contained
within is intended for direct or indirect distribution within the United
States of America, Canada, Australia or Japan.
phone: +49 (0)69-21 93 96 111 fax: +49
(0)69-21 93 96 122 e-mail: presse@nanostart.de
Media Contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail: presse@nanostart.de
|
Press
Releases